

1651



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

JAN 23 2003

TECH CENTER 1600/2900

Applicant: Kevin McGrath
Title: PEPTIDE ACTIVATORS OF VEGF

Docket No.: 1443.025US1
Filed: December 21, 2001
Examiner:

Serial No.: 10/032,361
Due Date: N/A
Group Art Unit: 1651

Commissioner for Patents
Washington, D.C. 20231

We are transmitting herewith the following attached items (as indicated with an "X"):

- ☒ A return postcard.
☒ An Information Disclosure Statement (1 pg.), Form 1449 (1 pg.), and copies of 16 cited references.

Please consider this a PETITION FOR EXTENSION OF TIME for sufficient number of months to enter these papers and please charge any additional required fees or credit overpayment to Deposit Account No. 19-0743.

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.
P.O. Box 2938, Minneapolis, MN 55402 (612-373-6900)

By: Robin A. Chadwick
Atty: Robin A. Chadwick
Reg. No. 36,477

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231, on this 15 day of January, 2003.

Name Gina M. Uphus


Gina Uphus
Signature

Customer Number 21186

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.

(GENERAL)

P.O. Box 2938, Minneapolis, MN 55402 (612-373-6900)



Jan 13 03 10:22p

robin chadwick

516-795-6820

p.2

N 10/032,361

IN THE UNITED STATES PATENT AND TRADEMARK OFFICEPATENT

Applicant: Kevin McGrath

Serial No.: 10/032,361

Filed: December 21, 2001

Title: PEPTIDE ACTIVATORS OF VEGF

Examiner:

Group Art Unit: 1651

Docket: 1443.025US1

#5
4.92
2/13/03
RECEIVED

JAN 23 2003

INFORMATION DISCLOSURE STATEMENTAssistant Commissioner for Patents
Washington, D.C. 20231

TECH CENTER 1600/2900

In compliance with the duty imposed by 37 C.F.R. § 1.56, and in accordance with 37 C.F.R. §§ 1.97 *et. seq.*, the enclosed materials are brought to the attention of the Examiner for consideration in connection with the above-identified patent application. Applicant respectfully requests that this Information Disclosure Statement be entered and the documents listed on the attached Form 1449 be considered by the Examiner and made of record. Pursuant to the provisions of MPEP 609, Applicant requests that a copy of the 1449 form, initialed as being considered by the Examiner, be returned to the Applicant with the next official communication.

Pursuant to 37 C.F.R. §1.97(b), it is believed that no fee or statement is required with the Information Disclosure Statement. However, if an Office Action on the merits has been mailed, the Commissioner is hereby authorized to charge the required fees to Account No. 19-0743 in order to have this Information Disclosure Statement considered.

The Examiner is invited to contact the Applicant's Representative at the below-listed telephone number if there are any questions regarding this communication.

Respectfully submitted,

KEVIN MCGRATH

By his Representatives,

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.
P.O. Box 2938
Minneapolis, MN 55402
(516) 795-6820

Date Jan. 14, 2003

By

Robin A. Chadwick
Reg. No. 36,477

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: Commissioner of Patents, Washington, D.C. 20231, on this 15 day of January, 2003.

Name

Gina M. Uphus

Signature

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete If Known

Application Number	10/032361
Filing Date	December 21, 2001
First Named Inventor	McGrath, Kevin
Group Art Unit	1651
Examiner Name	Unknown

RECEIVED

JAN 23 2003

Attorney Docket No: 1443.025US1

TECH CENTER 1600/2900

US PATENT DOCUMENTS

Examiner Initial *	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Class	Subclass	Filing Date If Appropriate
--------------------	---------------------	------------------	---	-------	----------	----------------------------

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	Class	Subclass	T ²
--------------------	---------------------	------------------	---	-------	----------	----------------

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	✓	COCKMAN, M., et al. "Hypoxia Inducible Factor-alpha Binding and Ubiquitylation by the von Hippel-Lindau Tumor Suppressor Protein", <u>The Journal of Biological Chemistry</u> , 275(33), (2000), pp. 25733-25741	
	✓	DER, S., et al. "Identification of genes differentially regulated by interferon alpha, B, or gamma using oligonucleotide arrays", <u>Proc. Natl. Acad. Sci. USA</u> , 95, (1998), pp. 15623-15628	
	✓	GRADIN, K., et al. "Repression of Dioxin Signal Transduction in Fibroblasts", <u>The Journal of Biological Chemistry</u> , 274(19), (1999), pp. 13511-13518	
	✓	HOSSAIN, M., et al. "Induction of Vascular Endothelial Growth Factor in Human Astrocytes by Lead", <u>The Journal of Biological Chemistry</u> , 275(36), (2000), pp. 27874-27882	
	✓	HUANG, L., et al. "Regulation of hypoxia-inducible factor 1alpha is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway", <u>Proc. Natl. Acad. Sci. USA</u> , 95, (1998), pp. 7987-7992	
	✓	IYER, N., et al. "Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1alpha", <u>Genes & Development</u> , 12, (1998), pp. 149-162	
	✓	KAMURA, T., et al. "Activation of HIF1alpha ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex", <u>PNAS</u> , 97(19), (2000), pp. 10430-10435	
	✓	MATHUPALA, S., et al. "Glucose Catabolism in Cancer Cells: Identification and Characterization of A Marked Activation Response of The Type II Hexokinase Gene to Hypoxic Condition", <u>The American Society for Biochemistry and Molecular Biology, Inc.</u> , (2001), pp. 1-24	
	✓	SCHEID, A., et al. "Hypoxia-regulated gene expression in fetal wound regeneration and adult wound repair", <u>Pediatr. Surg. Int.</u> , 16, (2000), pp. 232-236	
	✓	SEMENZA, G., "HIF-1: mediator of physiological and pathophysiological hypoxia", <u>J. Appl. Physiol.</u> , 88, (2000), pp. 1474-1480	
	✓	SUTTER, C., et al. "Hypoxia-inducible factor 1alpha protein expression in controlled by oxygen-regulated ubiquitination that is disrupted by deletions and missense mutations", <u>PNAS</u> , 97(9), (2000), pp. 4748-4753	
	✓	TAKAHASHI, Y., et al. "Hypoxic Induction of Prolyl 4-Hydroxylase alpha(I) in Cultured Cells", <u>The Journal of Biological Chemistry</u> , 275(19), (2000), pp. 14139-14146	

EXAMINER

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number 10/032361**Filing Date** December 21, 2001**First Named Inventor** McGrath, Kevin**Group Art Unit** 1651**Examiner Name** Unknown**Attorney Docket No:** 1443.025US1

Sheet 2 of 2

TECH CENTER 1600/2900

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	✓	TANIMOTO, K., et al. , "Mechanism of regulation of the hypoxia-inducible factor-1alpha by the von Hippel-Lindau tumor suppressor protein", <u>The EMBO Journal</u> , 19(16), (2000), pp. 4298-4309	
	✓	WENGER, R., "Review - Mammalian Oxygen Sensing, Signalling and Gene Regulation", <u>The Journal of Experimental Biology</u> , 203, (2000), pp. 1253-1263	
	✓	YU, F., et al. , "HIF-1alpha binding to VHL is regulated by stimulus-sensitive proline hydroxylation", <u>PNAS</u> , 98(17), (2001), pp. 9630-9635	
	✓	ZHONG, H., et al. , "Overexpression of Hypoxia-inducible Factor 1alpha in Common Human Cancers and Their Metastases", <u>Cancer Research</u> , 59, (1999), pp. 5830-5835	

EXAMINER**DATE CONSIDERED**

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached